Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis

Table 3

Associations of clinical and demographic variables with acute-phase response following zoledronic acid infusion.

Characteristics	Unadjusted		Model 1		Model 2
	OR (95% CI)	value	OR (95% CI)	value	OR (95% CI)	value
Age	0.97 (0.95–0.99)	0.002	0.94 (0.92–0.97)	<0.001	0.95 (0.92–0.98)	0.004
Prior oral BP	0.51 (0.31–0.82)	0.005	0.33 (0.16–0.65)	0.002	0.28 (0.12–0.64)	0.003
CTX	1.61 (1.04–2.48)	0.031	1.20 (0.72–1.98)	0.473	—	—
ΔCTX	0.53 (0.36–0.79)	0.002	—	—	0.60 (0.39–0.92)	0.019

BP, bisphosphonate; CTX (baseline), carboxy-terminal crosslinked telopeptide of type 1 collagen; ΔCTX: delta carboxy-terminal crosslinked telopeptide of type 1 collagen, calculated as log; OR: odds ratio. Model 1 included log-transformed baseline CTX, age, and prior oral bisphosphonate use. This study included 258 patients with complete data. Model 2 included log-transformed ΔCTX, age, and prior use of oral bisphosphonate. This study included 180 patients with complete data.